

FACTORS ASSOCIATED WITH CANNABIS USE AMONG INPATIENTS WITH INFLAMMATORY BOWEL DISEASE EXACERBATION

E Oseni, MD, M Blumenthal, S Izard, M Qiu, A Mone, MD, A Swaminath, MD, K Sultan, MD
Center for Health Innovations and Outcomes Research, Department of Medicine
Biostatistics Unit, Feinstein Institute of Medical Research



BACKGROUND

- Opioid use for inflammatory bowel disease (IBD) has been associated with an increased risk of disease complications
- Many IBD patients view cannabis use as a safer palliative alternative to opioids
- This study aimed to investigate cofactors associated with cannabis use as a first step before analysis of its impact on patient clinical outcomes
- Note: This research study did not receive any financial support. The investigators retained full independence in the conduct of this research.

METHODS

- A retrospective chart review was conducted of all adult patients admitted for an IBD exacerbation between 2016 and 2020, within the Northwell Healthcare System
- Manual chart review confirmed cannabis use.
- Cofactors including IBD type, age, gender, race, anxiety, depression, alcohol and tobacco use, CCI, inpatient opioid use and hospital length of stay were identified.
- An adjusted analysis was performed of cofactors to determine any association with cannabis use

STUDY POPULATION

- 1021 patients were identified; 47.40% with Crohn's Disease (CD) and 53.09% with Ulcerative Colitis (UC)
- Mean age was 45.28 (SD +/- 20.24). 72.77% of patients were < 60 years
- Pre-admission cannabis use was reported by 7.25%

FIG. 1: CANNABIS USE CLASSIFICATION FIG. 2: PATIENT CHARACTERISTICS 45.28 (20.24) 542 (53.09) 479 (46.91) Unknown, 15% 54 (5.29) 143 (14.01) 674 (66.01) 74 (7.25) 947 (92.75) Alcohol use 24 (2.35) Recreational 132 (12.93) 484 (47.40) 537 (52.60) 2.17 (2.88) LOS (days) 6.39 (7.11)

FIG. 3: PRE-ADMISSION CHARACTERISTICS AND CANNABIS USE

	(n=74), n (%)	(n=947), n (%)	(95% CI)		(95% CI)	
Patient characteristics						
Age (years)						
Mean (SD)	36.46 (15.52)	45.97 (20.41)	0.98 (0.96, 0.99)	0.0001	0.96 (0.94, 0.99)	0.0009
Gender						
Female	22 (29.73)	520 (54.91)	0.35 (0.21, 0.58)	<0.0001	0.28 (0.16, 0.50)	<0.000
Male	52 (70.27)	427 (45.09)	(REF)		(REF)	
Race						
African American/ Black	21 (28.38)	129 (13.62)	2.51 (1.44, 4.40)	0.0012	2.83 (1.52, 5.27)	0.0011
Asian	3 (4.05)	51 (5.39)	0.91 (0.27, 3.04)	0.8757	1.12 (0.32, 3.97)	0.8622
Other/ Multiracial	9 (12.16)	134 (14.15)	1.04 (0.49, 2.19)	0.9240	1.11 (0.50, 2.47)	0.8016
White	41 (55.41)	633 (66.84)	(REF)		(REF)	
Tobacco use						
Current	17 (22.97)	83 (8.76)	3.31 (1.78, 6.15)	0.0002	2.95 (1.46, 5.96)	0.0025
Former	12 (16.22)	160 (16.90)	1.21 (0.62, 2.38)	0.5800	1.72 (0.79, 3.74)	0.1721
Never	36 (48.65)	581 (61.35)	(REF)		(REF)	
Unknown	9 (12.16)	123 (12.99)	1.18 (0.56, 2.52)	0.6664	1.27 (0.50, 3.21)	0.6114
Alcohol use						
Current	17 (22.97)	162 (17.11)	1.32 (0.71, 2.47)	0.3794	1.03 (0.52, 2.05)	0.9246
Former	6 (8.11)	18 (1.90)	4.2 (1.55, 11.37)	0.0047	3.75 (1.21, 11.59)	0.0218
Never	30 (40.54)	378 (39.92)	(REF)		(REF)	
Unknown	21 (28.38)	389 (41.08)	0.68 (0.38, 1.21)	0.1893	0.51 (0.25, 1.04)	0.0647
Clinical characteristics						
Anxiety						
Yes	14 (18.92)	91 (9.61)	2.20 (1.18, 4.08)	0.0130	2.76 (1.31, 5.81)	0.0074
No	60 (81.08)	856 (90.39)	(REF)		(REF)	
Depression						
Yes	12 (16.22)	53 (5.60)	3.27 (1.66, 6.43)	0.0006	4.07 (1.80, 9.20)	0.0007
No	62 (83.78)	894 (94.40)	(REF)		(REF)	
IBD type						
Crohn's disease	42 (56.76)	442 (46.67)	0.67 (0.41, 1.08)	0.0961		
Ulcerative colitis	32 (43.24)	505 (53.33)	(REF)			
CCI						
Mean (SD)	1.35 (2.35)	2.23 (2.90)	0.87 (0.78, 0.97)	0.0124	0.97 (0.83, 1.13)	0.7044

RESULTS

- Factors found to be significantly associated with cannabis use include: age (younger), gender (males), race (African Americans), tobacco use, former alcohol use, anxiety and depression.
- These associations were found to be significant on both univariable and multivariable analysis (Fig 3).
- CCI was associated with cannabis use on univariable but not multivariable analysis.
- Cannabis use was most reported to be used by patients recreationally (Fig 1).

CONCLUSION

- Finding suggest that among IBD patients, cannabis use may be less associated with disease activity than with other patient characteristics.
- Further analysis of the impact of cannabis use on IBD outcomes is needed.
- Limitations of the study include possible underreporting and under-documentation of cannabis use, the inability to track cannabis use post-discharge and the inability to account for other factors that may contribute to contribute to cannabis use such as disease severity, duration and socioeconomic status.

About Northwell Health

As New York State's largest health care provider and private employer, Northwell Health strives to improve the health of the communities it serves and is committed to providing the highest quality clinical care; educating the current and future generations of health care professionals; searching for new advances in medicine through the conduct of bio-medical research; promoting health education; and caring for the entire community regardless of the ability to pay. Much more than a health system, we pioneer discoveries at the Feinstein Institute for Medical Research, provide visionary education at the Zucker School of Medicine at Hofstra/Northwell and School of Graduate Nursing and Physician Assistant Studies, and innovate through Northwell Ventures. The winner of the National Quality Forum's 2010 National Quality Healthcare Award, Northwell Health cares for people at every stage of life at 23 hospitals and more than 700 outpatient facilities throughout the region. Northwell Health encompasses more than 13,600 affiliated physicians, including about 4,000 employed doctors and nearly 3,300 members of Northwell Health Physician Partners. For more information, go to northwell.edu.